Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for PuriBlood Medical Co's Pretax Margin % or its related term are showing as below:
ROCO:6847'
s Pretax Margin % Range Over the Past 10 Years
Min: -731.05 Med: -45.27 Max: 12.32
Current: -47.08
ROCO:6847's Pretax Margin % is ranked worse than 74.75% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs ROCO:6847: -47.08
PuriBlood Medical Co (ROCO:6847) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
PuriBlood Medical Co Pretax Margin % Related Terms
PuriBlood Medical Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for PuriBlood Medical Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6847 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, PuriBlood Medical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuriBlood Medical Co Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where PuriBlood Medical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuriBlood Medical Co (ROCO:6847) has a Pretax Margin % of -57.26% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PuriBlood Medical Co and its competitors. According to the industry distribution chart, PuriBlood Medical Co ranks #151 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 74.8%.
Is PuriBlood Medical Co's Pretax Margin % too high?
PuriBlood Medical Co's current Pretax Margin % is -57.26%. Based on the distribution chart, PuriBlood Medical Co ranks #151 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PuriBlood Medical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PuriBlood Medical Co ranks #151 out of 202 companies for Pretax Margin %. This places PuriBlood Medical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PuriBlood Medical Co and its competitors. PuriBlood Medical Co's current Pretax Margin % is -57.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$66.17, compared to a current price of NT$77.70 — trading 17.4% above its estimated fair value. The current Pretax Margin % is -57.26%. PuriBlood Medical Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Pretax Margin % is -57.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?
Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued.
The current stock price of NT$77.70 is trading 17.4% above its estimated GF Value™ of NT$66.17.
GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.
Key valuation signals for ROCO:6847:
Pretax Margin %: -57.26%
GF Value™: NT$66.17 vs. price of NT$77.70 (17.4% above fair value)
No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
74GF Score
Get the complete analysis for ROCO:6847
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6847 has been successfully added to your 
